Carcinoma Of The Bile Duct - Pipeline Review, Q2 2011

Description: Carcinoma Of The Bile Duct - Pipeline Review, Q2 2011

Summary

Global Markets Direct's, 'Carcinoma Of The Bile Duct - Pipeline Review, Q2 2011', provides an overview of the Carcinoma Of The Bile Duct therapeutic pipeline. This report provides information on the therapeutic development for Carcinoma Of The Bile Duct, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Carcinoma Of The Bile Duct. 'Carcinoma Of The Bile Duct - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note:- Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Carcinoma Of The Bile Duct.
- A review of the Carcinoma Of The Bile Duct products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Carcinoma Of The Bile Duct pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Carcinoma Of The Bile Duct.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Carcinoma Of The Bile Duct pipeline depth and focus of Carcinoma Of The Bile Duct therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Carcinoma Of The Bile Duct Overview
Therapeutics Development
An Overview of Pipeline Products for Carcinoma Of The Bile Duct
Carcinoma Of The Bile Duct Therapeutics under Development by Companies
Carcinoma Of The Bile Duct Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Carcinoma Of The Bile Duct Therapeutics - Products under Development by Companies
Carcinoma Of The Bile Duct Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Carcinoma Of The Bile Duct Therapeutics Development
Steba Laboratories Ltd.
Carcinoma Of The Bile Duct - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Chloroquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FOLFIRI - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stakel Mediated VTP Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + 5FU + Leucovorin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mFOLFOX6 + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
3-AP + Gemcitabine for Gallbladder Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tamoxifen + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Foscan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti-thymocyte globulin + cyclophosphamide + cyclosporine + fludarabine phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UFT + Leucovorin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine - Drug Profile
List of Tables
Number of Products Under Development for Carcinoma Of The Bile Duct, Q2 2011
Products under Development for Carcinoma Of The Bile Duct – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Steba Laboratories Ltd., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011

List of Figures
Number of Products under Development for Carcinoma Of The Bile Duct, Q2 2011
Products under Development for Carcinoma Of The Bile Duct – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Ordering:
Order Online - http://www.researchandmarkets.com/reports/1801424/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Carcinoma Of The Bile Duct - Pipeline Review, Q2 2011
Web Address: http://www.researchandmarkets.com/reports/1801424/
Office Code: SCD2LPJP

Product Formats
Please select the product formats and quantity you require:

Quantity
Electronic (PDF) - Single User: □ USD 500
Electronic (PDF) - Site License: □ USD 1000
Electronic (PDF) - Enterprisewide: □ USD 1500

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: □ Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ________________________________ Last Name: ________________________________
Email Address: * ________________________________
Job Title: __________________________________
Organisation: ________________________________
Address: ___________________________________
City: _______________________________________
Postal / Zip Code: ____________________________
Country: ____________________________________
Phone Number: _______________________________
Fax Number: _________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:

You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:

Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World